Follow us on  LinkedFit for Health LinkedIN

Frequently Asked Questions (FAQ) - FTI-Specific aspects

Answer: 

“on the market” can be sale of device after completion of clinical trials. But out-licensing after Phase 2 can be considered as market uptake.

Question details: 
What would happen, if a Phase 2 is funded, but the company owning the drug candidate decides afterwards to develop the program further through Phase 3 to market (and thus does no longer comply with the 36-months-to-market dogma)?
Answer: 

Not reaching this goal will most probably have negative effects for the evaluation of the FTI instrument, but there will be no penalty for the consortium.

Answer: 

You should have the EU market in focus. If you can also deliver solutions for additional markets you can do so.

Answer: 

There is no other limitation than the fact that the time to market-uptake has to be no later than 3 years after the beginning of the project. So the project must not exceed 3 years. Expected are projects of 1-2 years.

Answer: 

Although there are no formal limits in the Work Programme, you should note that in terms of impact, the expectation is that initial market take-up of the innovation should happen no later than 36 months after the start of the action.

Answer: 

A dissemination plan is highly dependent on your project! There is not such a template.

Question details: 
For a proposal of an Active Pharmaceutical Ingredient (API) manufacturing method development the target is pharmaceutical industry market. Would it be applicable to FTI?
Answer: 

There are no limitations for target markets.

Answer: 

There is no penalty. You must convincingly explain this time to market, which risks you could face and how you could overcome them.

Answer: 

You must sound convincing in your application and offer solutions for overcoming that risk